secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-07-30T11:05:07+00:00
Accession:  0001193125-26-324865
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q2 revenue $74.3M (+88% YoY); net loss narrows to $17.6M; initiates Phase 3 NERD trial
--------------------------------------------------------------------------------

- Record Q2 net revenue $74.3M, up 88% YoY and 27% QoQ; operating expenses $63.1M, down 33% YoY.
- Net loss $17.6M vs $75.8M in Q2 2025; non-GAAP adjusted net loss nearly zero at $0.1M.
- ~325,000 VOQUEZNA prescriptions in Q2 (+88% YoY); ~1.7M total to date.
- Initiating Phase 3 trial for as-needed VOQUEZNA in NERD; first enrollment expected Q4 2026.
- Completed enrollment in Phase 2 EoE trial; topline results expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/0001193125-26-324865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer